FDA Clears Golimumab Biosimilars - Summary - MDSpire

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

  • By

  • Kathryn Wighton

  • May 18, 2026

  • 2 min

Share

Objective:

To report on the FDA's approval of Immgolis and Immgolis Intri as interchangeable biosimilars to Simponi and Simponi Aria for rheumatoid arthritis and ulcerative colitis.

Key Findings:
  • Immgolis and Immgolis Intri are the first interchangeable biosimilars for golimumab.
  • Pharmacokinetic analyses showed similar exposure and immunogenicity profiles.
  • Interchangeable biosimilars allow for pharmacy-level substitution under FDA standards.
Interpretation:

The approval of these biosimilars is expected to provide lower-cost treatment options while maintaining comparable clinical outcomes to the reference biologics.

Limitations:
  • The safety profile includes risks of serious infections and malignancies.
  • Common adverse events reported are similar to those of the reference products.
Conclusion:

The introduction of Immgolis and Immgolis Intri represents a significant advancement in treatment options for rheumatoid arthritis and ulcerative colitis, potentially improving access to care.

Original Source(s)

FDA Clears Golimumab Biosimilars

  • by Kathryn Wighton

  • May 18, 2026

Related Content

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Culture Mismatch Common in Joint Infections

Multicenter study suggests variability across centers and higher mismatch in certain clinical settings.

7 Days Noninferior in Bacteremia

BALANCE compared 7 vs 14 days of treatment among hospitalized patients with bloodstream infections.